Iovance Biotherapeutics (IOVA) Operating Leases (2019 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Operating Leases of $43.9 million for Q1 2026, down 0.78% year-over-year from $44.2 million in Q1 2025, and down 1.18% quarter-over-quarter from $44.4 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Operating Leases (2019 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Operating Leases for 8 consecutive years, with $43.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 0.78% year-over-year to $43.9 million; the TTM figure through Mar 2026 stood at $43.9 million (down 0.78% YoY), while the FY2025 annual figure was $44.4 million, changed 0.08% from the prior year.
- Operating Leases retreated to $43.9 million in Q1 2026 per IOVA's latest filing, from $44.4 million in the prior quarter.
- Across five years, Operating Leases topped out at $73.0 million in Q2 2022 and bottomed at $43.9 million in Q1 2026.
- Historically, Operating Leases has averaged $60.1 million across 5 years, with a median of $68.0 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Leases surged 55.83% — and 2025, when it sank 38.83%.
- Iovance Biotherapeutics' Operating Leases stood at $71.9 million in 2022, then slipped by 6.64% to $67.1 million in 2023, then sank by 33.87% to $44.4 million in 2024, then climbed by 0.08% to $44.4 million in 2025, then dropped by 1.18% to $43.9 million in 2026.
- Business Quant data shows IOVA's Operating Leases at $43.9 million in Q1 2026, $44.4 million in Q4 2025, and $45.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.33 Mn |
| Mar 31, 2026 | 43.88 Mn |
| Dec 31, 2025 | 44.40 Mn |
| Sep 30, 2025 | 45.21 Mn |
| Jun 30, 2025 | 45.10 Mn |
| Mar 31, 2025 | 44.22 Mn |
| Dec 31, 2024 | 44.37 Mn |
| Mar 31, 2024 | 72.29 Mn |
| Dec 31, 2023 | 67.09 Mn |
| Sep 30, 2023 | 68.01 Mn |
| Jun 30, 2023 | 68.84 Mn |
| Mar 31, 2023 | 69.61 Mn |
| Dec 31, 2022 | 71.86 Mn |
| Sep 30, 2022 | 71.94 Mn |
| Jun 30, 2022 | 73.00 Mn |
| Mar 31, 2022 | 71.18 Mn |
| Dec 31, 2021 | 65.47 Mn |
| Sep 30, 2021 | 64.73 Mn |
| Jun 30, 2021 | 46.84 Mn |
| Mar 31, 2021 | 47.08 Mn |